2015
Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials)
Ng VG, Baumbach A, Grinfeld L, Lincoff AM, Mehran R, Stone GW, Lansky AJ. Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). The American Journal Of Cardiology 2015, 117: 186-191. PMID: 26704028, DOI: 10.1016/j.amjcard.2015.10.029.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionStrong independent predictorMajor bleedingMortality rateBivalirudin therapyCoronary interventionIndependent predictorsFemale genderGlycoprotein IIb/IIIa inhibitor treatmentST-segment elevation myocardial infarctionNon-coronary artery bypassPatient-level pooled analysisImpact of bleedingMajor bleeding ratesPronounced clinical benefitOutcomes of patientsAcute coronary syndromeCohort of patientsElevation myocardial infarctionArtery bypassCoronary syndromeMultivariate adjustmentStandard therapyClinical benefitPooled analysis
2011
Three-Year Results of Safety and Efficacy of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III Randomized Clinical Trial)
Ng VG, Lansky AJ, Hermiller JB, Farhat N, Applegate RJ, Yaqub M, Sood P, Su X, Simonton CA, Sudhir K, Stone GW. Three-Year Results of Safety and Efficacy of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III Randomized Clinical Trial). The American Journal Of Cardiology 2011, 107: 841-848. PMID: 21255760, DOI: 10.1016/j.amjcard.2010.10.068.Peer-Reviewed Original ResearchConceptsTarget vessel failure rateSPIRIT III trialXIENCE VIII trialsClinical outcomesLow major adverse cardiac event rateMajor adverse cardiac event ratesAdverse cardiac event ratesMajor adverse cardiac eventsTAXUS paclitaxel-eluting stentAdverse cardiac eventsCardiac event rateCoronary artery lesionsLong-term complicationsPaclitaxel-eluting stentsThree-year resultsLesion revascularizationArtery lesionsCardiac eventsComplication rateStent thrombosisTreatment armsClinical benefitTaxus stentSubset analysis
2010
Selection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Stone GW, Parise H, Witzenbichler B, Kirtane A, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Lansky AJ, Mehran R. Selection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. Journal Of The American College Of Cardiology 2010, 56: 1597-1604. PMID: 20888162, DOI: 10.1016/j.jacc.2010.08.608.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPaclitaxel-eluting stentsBare metal stentsDrug-eluting stentsElevation myocardial infarctionRisk factorsMyocardial infarctionClinical benefitVersus Bare-Metal StentsAbsolute incremental benefitHORIZONS-AMI trialBaseline risk factorsReference vessel diameterAngiographic Follow-upAbsolute treatment effectLesion revascularizationTLR proceduresTLR rateDiabetes mellitusIndependent predictorsRisk strataFollow-upRisk groupsHigh riskAntirestenotic properties
2009
Gender‐based evaluation of the XIENCE V™ everolimus‐eluting coronary stent system:
Lansky AJ, Ng VG, Mutlu H, Cristea E, Guiran JB, Midei M, Newman W, Sanz M, Sood P, Doostzadeh J, Su X, White R, Cao S, Sudhir K, Stone GW. Gender‐based evaluation of the XIENCE V™ everolimus‐eluting coronary stent system:. Catheterization And Cardiovascular Interventions 2009, 74: 719-727. PMID: 19530147, DOI: 10.1002/ccd.22067.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCardiovascular DiseasesCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateLinear ModelsLogistic ModelsMaleMiddle AgedMyocardial InfarctionPaclitaxelProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsSex FactorsSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeWomen's HealthConceptsSPIRIT III trialIII trialsXIENCE VTaxus stentXience V stentTVF rateTAXUS paclitaxel-eluting stentRate of MACECoronary artery lesionsStent thrombosis ratesPercutaneous coronary interventionStent late lossPaclitaxel-eluting stentsCoronary stent systemHigher MACEMore hypertensionAngiographic characteristicsArtery lesionsCoronary interventionThrombosis rateAngiographic resultsClinical outcomesClinical benefitStent placementSubset analysis
2007
Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation
Solinas E, Nikolsky E, Lansky AJ, Kirtane AJ, Morice MC, Popma JJ, Schofer J, Schampaert E, Pucelikova T, Aoki J, Fahy M, Dangas GD, Moses JW, Cutlip DE, Leon MB, Mehran R. Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation. Journal Of The American College Of Cardiology 2007, 50: 2111-2116. PMID: 18036446, DOI: 10.1016/j.jacc.2007.06.056.Peer-Reviewed Original ResearchConceptsSirolimus-eluting stentsBare metal stentsSegment binary restenosisBinary restenosisClinical outcomesMajor adverse cardiac eventsSirolimus-Eluting Stent ImplantationAdverse cardiac eventsOutcomes of patientsTarget vessel revascularizationCongestive heart failureOutcomes of womenPercutaneous coronary interventionOverall clinical outcomeGender-specific differencesVessel revascularizationCardiac eventsCoronary interventionAngiographic featuresDiabetes mellitusHeart failureIndependent predictorsMultivariable analysisClinical benefitStent implantation
1999
Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction
Grines C, Cox D, Stone G, Garcia E, Mattos L, Giambartolomei A, Brodie B, Madonna O, Eijgelshoven M, Lansky A, O'Neill W, Morice M. Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction. New England Journal Of Medicine 1999, 341: 1949-1956. PMID: 10607811, DOI: 10.1056/nejm199912233412601.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionTarget vessel revascularizationAngioplasty groupStent groupMyocardial infarctionPrimary angioplastyCoronary angioplastyStent implantationMean minimal luminal diameterSix-month mortality rateEnd pointCombined end pointPrimary end pointPrimary coronary angioplastyCoronary stent implantationMinimal luminal diameterRoutine implantationClinical benefitMulticenter studyEmergency catheterizationLower incidenceLuminal diameterAngioplastyBlood flowMortality rate
1996
Contemporary stent designs: Technical considerations, complications, role of intravascular ultrasound, and anticoagulation therapy
Popma J, Lansky A, Ito S, Mintz G, Leon M. Contemporary stent designs: Technical considerations, complications, role of intravascular ultrasound, and anticoagulation therapy. Progress In Cardiovascular Diseases 1996, 39: 111-128. PMID: 8841006, DOI: 10.1016/s0033-0620(96)80021-1.Peer-Reviewed Original ResearchConceptsBalloon angioplastyIntravascular ultrasoundSaphenous vein graft diseaseClinical useLate clinical benefitNative coronary arteriesVein graft diseaseStent designCurrent antiplateletAnticoagulation therapyAntithrombotic therapyGraft diseaseAdjunct therapyClinical benefitCoronary arteryStent placementDiffuse diseaseStent useBifurcation stenosisTherapySmall vesselsAngioplastyComplicationsNumber of studiesDisease